Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children
| Autor: | Rudin, Christoph, Wolbers, Marcel, Nadal, David, Rickenbach, Martin, Bucher, Heiner C, the Pediatric Infectious Disease Group of Switzerland (PIGS), the Swiss Mother and Child HIV Cohort Study (MoCHiV) |
|---|---|
| Přispěvatelé: | University of Zurich, Rudin, C, Diana, Alessandro, Gervaix, Alain, Myers, Catherine Jayne, Posfay Barbe, Klara, Siegrist, Claire-Anne, Wyler, Claire-Anne |
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Population Lopinavir/ritonavir HIV Infections 610 Medicine & health Pyrimidinones ddc:616.07 Lopinavir immune system diseases Interquartile range Internal medicine HIV-1/isolation & purification medicine Humans Prospective Studies 2735 Pediatrics Perinatology and Child Health Child Prospective cohort study education Ritonavir/adverse effects/therapeutic use education.field_of_study Ritonavir ddc:618 HIV Infections/drug therapy/immunology/virology business.industry virus diseases HIV Protease Inhibitors Viral Load CD4 Lymphocyte Count Treatment Outcome Pyrimidinones/adverse effects/therapeutic use 10036 Medical Clinic Child Preschool Pediatrics Perinatology and Child Health Immunology Cohort HIV-1 Drug Therapy Combination Female HIV Protease Inhibitors/adverse effects/therapeutic use business Viral load Follow-Up Studies medicine.drug |
| Zdroj: | Archives of Disease in Childhood, Vol. 95, No 6 (2010) pp. 478-81 |
| ISSN: | 1468-2044 0003-9888 |
| DOI: | 10.1136/adc.2009.169375 |
| Popis: | AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children. METHODS: All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included. RESULTS: 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45-3.17; PI-naive, n=17) and 2.53 (3.68-1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203-593; PI-naive) and 177 (21-331; PI-experienced) cells/microl. These effects remained stable throughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children. CONCLUSION: Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|